<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27136962</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>12</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>10</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1539-2031</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>51</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>01</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of clinical gastroenterology</Title>
                <ISOAbbreviation>J. Clin. Gastroenterol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Endoscopic Variceal Ligation followed by Argon Plasma Coagulation Against Endoscopic Variceal Ligation Alone: A Randomized Controlled Trial.</ArticleTitle>
            <Pagination>
                <MedlinePgn>49-55</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="GOALS">Our aim was to study the efficacy and the safety of argon plasma coagulation (APC) in secondary prophylaxis against esophageal varices in view of many contraindications and side effects to β-blockers in cirrhotic patients.</AbstractText>
                <AbstractText Label="BACKGROUND">Rebleeding rates from esophageal varices after endoscopic variceal ligation (EVL) are high; thus, the current recommendation is to combine nonselective β-blockers to it, but side effects and relative contraindications to nonselective β-blockers hinder their usage or require discontinuation in 15% to 20% of the cirrhotic patients. Thus, it is important to find another combination.</AbstractText>
                <AbstractText Label="STUDY">This study included all patients admitted to the Alexandria Main University Hospital during the period between April 2012 and October 2012 with variceal bleeding. After exclusions, the total number of included patients was 40. All participants were subjected to EVL and eradication of varices, and then they were randomized to either APC (group 1) or just observation (group 2). Both groups were followed up by endoscopy every 3 months for 30 months.</AbstractText>
                <AbstractText Label="RESULTS">During the 2.5-year follow-up, 21% of the participants in group 1 experienced esophageal variceal recurrence, but no one needed rebanding. In group 2, 68.4% of the participants experienced esophageal variceal recurrence (P=0.003) and 63.2% underwent rebanding (P&lt;0.001).</AbstractText>
                <AbstractText Label="CONCLUSIONS">APC after esophageal variceal eradication using EVL can decrease the risk of recurrence of esophageal varices and the need for rebanding. This technique may be recommended in secondary prophylaxis against esophageal variceal bleeding in those who have contraindications, are intolerant, or are noncompliant to nonselective β-blockers.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kamal</LastName>
                    <ForeName>Ahmed</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>*Hepatology Unit †Head and Neck Surgery Unit, Alexandria University, Alexandria, Egypt.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abd Elmoety</LastName>
                    <ForeName>Amr A</ForeName>
                    <Initials>AA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamza</LastName>
                    <ForeName>Yasser</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zeid</LastName>
                    <ForeName>Ahmed</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Clin Gastroenterol</MedlineTA>
            <NlmUniqueID>7910017</NlmUniqueID>
            <ISSNLinking>0192-0790</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D057908" MajorTopicYN="N">Argon Plasma Coagulation</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004932" MajorTopicYN="N">Esophageal and Gastric Varices</DescriptorName>
                <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004945" MajorTopicYN="N">Esophagoscopy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004947" MajorTopicYN="N">Esophagus</DescriptorName>
                <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006471" MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName>
                <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008026" MajorTopicYN="N">Ligation</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>5</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>5</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27136962</ArticleId>
            <ArticleId IdType="doi">10.1097/MCG.0000000000000535</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>